553 related articles for article (PubMed ID: 22045636)
41. FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature.
Blomberg M; Jeppesen EM; Skovby F; Benfeldt E
Dermatology; 2010; 220(4):297-305. PubMed ID: 20453470
[TBL] [Abstract][Full Text] [Related]
42. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
Legeai-Mallet L
Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
[TBL] [Abstract][Full Text] [Related]
43. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
44. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.
Bellus GA; McIntosh I; Smith EA; Aylsworth AS; Kaitila I; Horton WA; Greenhaw GA; Hecht JT; Francomano CA
Nat Genet; 1995 Jul; 10(3):357-9. PubMed ID: 7670477
[TBL] [Abstract][Full Text] [Related]
45. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.
Lorget F; Kaci N; Peng J; Benoist-Lasselin C; Mugniery E; Oppeneer T; Wendt DJ; Bell SM; Bullens S; Bunting S; Tsuruda LS; O'Neill CA; Di Rocco F; Munnich A; Legeai-Mallet L
Am J Hum Genet; 2012 Dec; 91(6):1108-14. PubMed ID: 23200862
[TBL] [Abstract][Full Text] [Related]
47. Hypochondroplasia in a child with 1620C>G (Asn540Lys) mutation in FGFR3.
Korkmaz HA; Hazan F; Dizdarer C; Tükün A
J Clin Res Pediatr Endocrinol; 2012 Dec; 4(4):220-2. PubMed ID: 23149434
[TBL] [Abstract][Full Text] [Related]
48. Increased p21 expression in chondrocytes of achondroplasic children independently from the presence of the G380R FGFR3 mutation.
Parafioriti A; del Bianco S; Barisani D; Armiraglio E; Peretti G; Albisetti W
J Orthop Sci; 2009 Sep; 14(5):623-30. PubMed ID: 19802676
[TBL] [Abstract][Full Text] [Related]
49. FGFR3 mutations in benign skin tumors.
Hafner C; Vogt T; Hartmann A
Cell Cycle; 2006 Dec; 5(23):2723-8. PubMed ID: 17172848
[TBL] [Abstract][Full Text] [Related]
50. High frequency of FGFR3 mutations in adenoid seborrheic keratoses.
Hafner C; van Oers JM; Hartmann A; Landthaler M; Stoehr R; Blaszyk H; Hofstaedter F; Zwarthoff EC; Vogt T
J Invest Dermatol; 2006 Nov; 126(11):2404-7. PubMed ID: 16778799
[TBL] [Abstract][Full Text] [Related]
51. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
[TBL] [Abstract][Full Text] [Related]
52. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.
Qi H; Jin M; Duan Y; Du X; Zhang Y; Ren F; Wang Y; Tian Q; Wang X; Wang Q; Zhu Y; Xie Y; Liu C; Cao X; Mishina Y; Chen D; Deng CX; Chang Z; Chen L
Biochim Biophys Acta; 2014 Jul; 1843(7):1237-47. PubMed ID: 24657641
[TBL] [Abstract][Full Text] [Related]
53. Acanthosis nigricans and hypochondroplasia in a child with a K650Q mutation in FGFR3.
Berk DR; Boente Mdel C; Montanari D; Toloza MG; Primc NB; Prado MI; Bayliss SJ; Pique LM; Schrijver I
Pediatr Dermatol; 2010; 27(6):664-6. PubMed ID: 21510009
[TBL] [Abstract][Full Text] [Related]
54. Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene.
Leroy JG; Nuytinck L; Lambert J; Naeyaert JM; Mortier GR
Am J Med Genet A; 2007 Dec; 143A(24):3144-9. PubMed ID: 18000903
[TBL] [Abstract][Full Text] [Related]
55. A Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia.
Chen L; Li C; Qiao W; Xu X; Deng C
Hum Mol Genet; 2001 Mar; 10(5):457-65. PubMed ID: 11181569
[TBL] [Abstract][Full Text] [Related]
56. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
[TBL] [Abstract][Full Text] [Related]
57. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
[TBL] [Abstract][Full Text] [Related]
58. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
[TBL] [Abstract][Full Text] [Related]
59. An Fgfr3-activating mutation in immature murine osteoblasts affects the appendicular and craniofacial skeleton.
Biosse Duplan M; Dambroise E; Estibals V; Veziers J; Guicheux J; Legeai-Mallet L
Dis Model Mech; 2021 Apr; 14(4):. PubMed ID: 33737326
[TBL] [Abstract][Full Text] [Related]
60. Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible.
Biosse Duplan M; Komla-Ebri D; Heuzé Y; Estibals V; Gaudas E; Kaci N; Benoist-Lasselin C; Zerah M; Kramer I; Kneissel M; Porta DG; Di Rocco F; Legeai-Mallet L
Hum Mol Genet; 2016 Jul; 25(14):2997-3010. PubMed ID: 27260401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
